دورية أكاديمية
أعرض في EDS

Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis.

التفاصيل البيبلوغرافية
العنوان: Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis.
المؤلفون: Leibold J; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Ruscetti M; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Cao Z; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, New York., Ho YJ; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Baslan T; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Zou M; Departments of Pharmacology, Urology, Medicine, Pathology and Cell Biology, and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York., Abida W; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Feucht J; Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Han T; Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, New York.; Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York., Barriga FM; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Tsanov KM; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Zamechek L; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Kulick A; Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York., Amor C; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Tian S; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Rybczyk K; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Salgado NR; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Sánchez-Rivera FJ; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Watson PA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., de Stanchina E; Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York., Wilkinson JE; Department of Pathology, University of Michigan, Ann Arbor, Michigan., Dow LE; Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York., Abate-Shen C; Departments of Pharmacology, Urology, Medicine, Pathology and Cell Biology, and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York., Sawyers CL; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. lowes@mskcc.org sawyersc@mskcc.org.; Howard Hughes Medical Institute, Chevy Chase, Maryland., Lowe SW; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York. lowes@mskcc.org sawyersc@mskcc.org.; Howard Hughes Medical Institute, Chevy Chase, Maryland.
المصدر: Cancer discovery [Cancer Discov] 2020 Jul; Vol. 10 (7), pp. 1038-1057. Date of Electronic Publication: 2020 May 06.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : American Association for Cancer Research
مواضيع طبية MeSH: Prostatic Neoplasms/*genetics , Tissue Engineering/*methods , Wnt Signaling Pathway/*genetics, Animals ; Disease Models, Animal ; Female ; Humans ; Male ; Mice ; Neoplasm Metastasis
مستخلص: To study genetic factors influencing the progression and therapeutic responses of advanced prostate cancer, we developed a fast and flexible system that introduces genetic alterations relevant to human disease directly into the prostate glands of mice using tissue electroporation. These electroporation-based genetically engineered mouse models (EPO-GEMM) recapitulate features of traditional germline models and, by modeling genetic factors linked to late-stage human disease, can produce tumors that are metastatic and castration-resistant. A subset of tumors with Trp53 alterations acquired spontaneous WNT pathway alterations, which are also associated with metastatic prostate cancer in humans. Using the EPO-GEMM approach and an orthogonal organoid-based model, we show that WNT pathway activation drives metastatic disease that is sensitive to pharmacologic WNT pathway inhibition. Thus, by leveraging EPO-GEMMs, we reveal a functional role for WNT signaling in driving prostate cancer metastasis and validate the WNT pathway as therapeutic target in metastatic prostate cancer. SIGNIFICANCE: Our understanding of the factors driving metastatic prostate cancer is limited by the paucity of models of late-stage disease. Here, we develop EPO-GEMMs of prostate cancer and use them to identify and validate the WNT pathway as an actionable driver of aggressive metastatic disease. This article is highlighted in the In This Issue feature, p. 890 .
(©2020 American Association for Cancer Research.)
References: Nat Med. 2016 Apr;22(4):369-78. (PMID: 26928463)
Nat Rev Mol Cell Biol. 2007 Apr;8(4):331-6. (PMID: 17342185)
Nat Genet. 2011 May;43(5):491-8. (PMID: 21478889)
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11264-9. (PMID: 18685109)
Nat Rev Drug Discov. 2006 Dec;5(12):997-1014. (PMID: 17139285)
Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700)
Nature. 2014 Dec 18;516(7531):428-31. (PMID: 25337879)
PLoS Genet. 2009 Jul;5(7):e1000542. (PMID: 19578399)
Cell. 2018 Jul 26;174(3):758-769.e9. (PMID: 30033370)
Nat Biotechnol. 2017 Jun;35(6):569-576. (PMID: 28459449)
Cancer Discov. 2019 Oct;9(10):1358-1371. (PMID: 31337618)
Methods. 2019 Jul 15;164-165:100-108. (PMID: 30836137)
Nat Med. 2012 Sep;18(9):1359-68. (PMID: 22863786)
Nature. 2011 Nov 09;479(7374):547-51. (PMID: 22080947)
Nat Biotechnol. 2013 Mar;31(3):213-9. (PMID: 23396013)
Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Nature. 2009 Oct 1;461(7264):614-20. (PMID: 19759537)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
Oncogene. 2016 Jul 21;35(29):3781-95. (PMID: 26640144)
Nat Genet. 1995 Apr;9(4):401-6. (PMID: 7795646)
J Vis Exp. 2013 Oct 18;(80):e50710. (PMID: 24192750)
Genes Dev. 2014 Jan 1;28(1):85-97. (PMID: 24395249)
Nat Med. 2017 Jun;23(6):703-713. (PMID: 28481359)
Eur J Med Chem. 2017 Dec 15;142:506-522. (PMID: 29107427)
Cell. 2015 Jan 15;160(1-2):324-38. (PMID: 25557080)
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. (PMID: 31061129)
Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):. (PMID: 29661807)
Cancer Res. 2008 Apr 1;68(7):2132-44. (PMID: 18381418)
Nat Genet. 2013 Oct;45(10):1127-33. (PMID: 24071851)
Clin Cancer Res. 2019 Mar 15;25(6):1766-1773. (PMID: 30209161)
Molecules. 2018 Jun 05;23(6):. (PMID: 29874846)
Genes Dev. 2011 Oct 15;25(20):2125-36. (PMID: 21979375)
Cancer Res. 2012 Jun 1;72(11):2822-32. (PMID: 22440753)
Nat Protoc. 2016 Feb;11(2):347-58. (PMID: 26797458)
Nature. 2012 Jul 12;487(7406):239-43. (PMID: 22722839)
Cancer Res. 2015 Jul 1;75(13):2749-59. (PMID: 25948589)
Oncogene. 2016 Feb 11;35(6):702-14. (PMID: 25893287)
Nat Protoc. 2012 May 03;7(6):1024-41. (PMID: 22555242)
Nat Commun. 2016 Feb 26;7:10770. (PMID: 26916719)
J Pathol. 2017 Dec;243(4):442-456. (PMID: 29134654)
Mod Pathol. 2008 Sep;21(9):1156-67. (PMID: 18567993)
Genome Res. 2015 May;25(5):714-24. (PMID: 25858951)
Hum Gene Ther. 1994 Dec;5(12):1477-83. (PMID: 7711140)
Cancer Res. 2005 Dec 15;65(24):11565-71. (PMID: 16357166)
Eur Urol. 2019 Nov;76(5):562-571. (PMID: 30928160)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Nat Genet. 2018 May;50(5):645-651. (PMID: 29610475)
Cancer Discov. 2014 Mar;4(3):318-33. (PMID: 24444712)
Annu Rev Cell Dev Biol. 2004;20:781-810. (PMID: 15473860)
Nature. 2019 Jul;571(7765):408-412. (PMID: 31243370)
Cancer Cell. 2003 Sep;4(3):223-38. (PMID: 14522256)
Cancer Cell. 2010 Apr 13;17(4):376-87. (PMID: 20385362)
Nature. 2018 Oct;562(7725):69-75. (PMID: 30209397)
Oncotarget. 2017 May 23;8(21):35376-35389. (PMID: 28430640)
Cancer Res. 1957 Jun;17(5):467-72. (PMID: 13437311)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)
Nature. 2019 Aug;572(7770):538-542. (PMID: 31367040)
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7. (PMID: 27141961)
PLoS One. 2014 Apr 17;9(4):e95236. (PMID: 24743474)
Oncogene. 2019 Feb;38(7):913-934. (PMID: 30194451)
JCO Precis Oncol. 2017 Jul;2017:. (PMID: 28825054)
Nature. 2005 Apr 14;434(7035):843-50. (PMID: 15829953)
Cancer Res. 2016 Jan 15;76(2):283-92. (PMID: 26554830)
Mech Dev. 2001 Mar;101(1-2):61-9. (PMID: 11231059)
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44. (PMID: 25024180)
Nat Biotechnol. 2017 Jun;35(6):577-582. (PMID: 28459450)
Cell. 2015 Jul 16;162(2):454. (PMID: 28843286)
Cell. 2018 Apr 5;173(2):321-337.e10. (PMID: 29625050)
Cancer Cell. 2017 Oct 9;32(4):474-489.e6. (PMID: 29017058)
Pancreas. 2014 May;43(4):614-8. (PMID: 24713671)
Genes Dev. 2009 Apr 1;23(7):877-89. (PMID: 19339691)
معلومات مُعتمدة: R01 CA193837 United States CA NCI NIH HHS; P50 CA092629 United States CA NCI NIH HHS; R01 CA233944 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; R01 CA155169 United States CA NCI NIH HHS; P01 CA087497 United States CA NCI NIH HHS; U54 CA224079 United States CA NCI NIH HHS; R01 CA183929 United States CA NCI NIH HHS; T32 CA160001 United States CA NCI NIH HHS; U54 OD020355 United States OD NIH HHS; K99 CA241110 United States CA NCI NIH HHS; R01 CA173481 United States CA NCI NIH HHS; United States HHMI Howard Hughes Medical Institute
تواريخ الأحداث: Date Created: 20200508 Date Completed: 20211119 Latest Revision: 20221005
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7334089
DOI: 10.1158/2159-8290.CD-19-1242
PMID: 32376773
قاعدة البيانات: MEDLINE
الوصف
تدمد:2159-8290
DOI:10.1158/2159-8290.CD-19-1242